Mechanism of Increased Cancer Risk in HIV
DOI:
https://doi.org/10.47672/ejhs.522Keywords:
HIV, cancer, malignancy, antiretroviral therapy, oncogenesis, inflammationAbstract
Purpose: To critically appraise and explore the underlying mechanisms of increased cancer risk in HIV with a view to revealing novel opportunities in preventing and treating cancer in HIV.
Methodology:Literature search was carried out with the aid of PubMed, Google scholar and New England Journal of Medicine.
Findings: Different articles were reviewed to better understand the synergistic mechanisms of oncogenesis in HIV. Although, some mechanisms are largely unclear, evidences derived from several studies clarified the oncogenic mechanisms of some factors examined in this article. Immunodeficiency appears to be pivotal and fundamental to the proneness to cancer risk in HIV whereas evidence is emerging that a direct pro-oncogenic effect of HIV, chronic immune activation (inflammation), and possible carcinogenic effects of antiretroviral drug may also contribute. Furthermore, increasing age and lifestyle behaviors such as multiple sexual partners, anal sex, intravenous drug use and alcohol use could also contribute.
Unique Contribution to Theory, Practice and Policy:While the role of immunosuppression as a risk factor for malignancy in HIV is well established, other synergistic mechanisms have been in the shadows of clinical practice. This review explores novel mechanisms associated with rise in titre of inflammatory markers, direct effects of HIV tat and vpr molecules and oncogenic effects of anti-retroviral drugs.
Summary:Continued research on the mechanisms of cancer risk in HIV is advocated to better understand how to intervene to mitigate cancer risk. Possible exploration and investigation of the role of tat and vpr inhibitors is recommended as tat and vpr are highly implicated in the direct oncogenic effects of HIV.
Downloads
References
. Yarchoan R, Uldrick TS. 2018. HIV-associated cancers and related diseases. N Engl J Med 378:1029–1041. doi:10.1056/NEJMra1615896.
1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep1992;41(RR-17):1-19.
Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017;4(11):e495-e504.
Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002;94:1204-10
Borges AH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. CurrOpin HIV AIDS. (2014) 1:34–40. 10.1097/COH.0000000000000025
Dubrow R, Silverberg MJ, Park LS, et al. HIV infection, aging, and immune function: implications for cancer risk and prevention. CurrOpin Oncol. 2012;24:506–516. In depth review of the mechanisms postulated to lead to cancer risk in the setting of HIV infection. A detailed summary of available data on the association between CD4+ cell counts, as a proxy marker of immunodeficiency, and cancer risk is also provided.
Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337–2345.
Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune DeficSyndr. 2009;52:611–622.
Franzetti M, Adorni F, Parravicini C, et al. Trends and predictors of non AIDS-defining cancers in men and women with HIV infection. A single-institution retrospective study before and after the introduction of HAART. J Acquir Immune DeficSyndr. 2013;62:414–420.
Calabresi A, Ferraresi A, Festa A, et al. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999–2009. HIV Med. 2013;14:481–490.
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Ann Rev Immunol. 2011;29:235–271.
Morgan GJ, Linet MS, Rabkin CS. Immunologic factors. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer Epidemiology and Prevention. Oxford: Oxford University Press; 2006. pp. 549–561.
Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56:69–83.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899.
Borges AH, Silverberg MJ, Wentworth D, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013;27:1433–1441. This is the largest prospective study to investigate, in the setting of HIV infection, the relationship between plasma levels of coagulation (D-dimer) and inflammatory biomarkers (CRP and IL-6) and cancer risk.
El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957–1963.
Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009 Dec;10(12):1152–9
Bruyand M, Thiébaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: AgenceNationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49:1109–1116.
Zhou F, Xue M, Qin D, et al. HIV-1 Tat promotes Kaposi’s sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3β signaling pathway. PLoS One. 2013;8:e53145.
Amini S, Khalili K, Sawaya BE. Effect of HIV–1 Vpr on cell cycle regulators. DNA Cell Biol. 2004;23:249–260.
Harrod R, Nacsa J, Van Lint C, et al. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J Biol Chem. 2003;278:12310–12318.
Nunnari G, Smith JA, Daniel R. HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? Journal of Experimental & Clinical Cancer Research:CR.2008;27:3.DOI: 10.1186/1756-9966-27-3
Aoki Y, Tosato G. Targeted inhibition of angiogenic factors in AIDS-related disorders. Current Drug Targets – Infectious Disorders. 2003;3:115–128. doi: 10.2174/1568005033481222.
Nasti G, Tirelli U. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma (KS): implications for the design of therapeutic trials in patients with advanced symptomatic KS.[comment] Journal of Clinical Oncology. 2005;23:2433. doi: 10.1200/JCO.2005.05.790. author reply 2433–2434.
Reitz MS, Jr, Nerurkar LS, Gallo RC. Perspective on Kaposi's sarcoma: facts, concepts, and conjectures. Journal of the National Cancer Institute. 1999;91:1453–1458. doi: 10.1093/jnci/91.17.1453.
Aoki Y, Tosato G. Neoplastic conditions in the context of HIV-1 infection. Current HIV Research. 2004;2:343–349. doi: 10.2174/1570162043351002.
Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 1990;345:84–86. doi: 10.1038/345084a0.
Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis. 2002;5:141–151. doi: 10.1023/A:1023892223074.
Lorena Loarca, Joseph A. Fraietta, Vanessa Pirrone, ZsofiaSzep and Brian Wigdahl (February 22nd 2017). Human Immunodeficiency Virus (HIV) Infection and Cancer, HIV/AIDS - Contemporary Challenges, Nancy Dumais, IntechOpen, DOI: 10.5772/67162
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93(5):705–716.
Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Letters. 1995;372(1):83–87.
Merat R, Amara A, Lebbe C, de The H, Morel P, Saib A. HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation. International Journal of Cancer; Journal international du cancer. 2002;97(6):791–795.
Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P,
Gallo RC. Release, uptake and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. Journal of Virology. 1993;67
(1):277–287.
Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Molecular Biology of the Cell. 2004;15(5):2347–2360. DOI:
1091/mbc.E03-12-0921
Wu RF, Gu Y, Xu YC, Mitola S, Bussolino F, Terada LS. Human immunodeficiency virus type 1 Tat regulates endothelial cell actin cytoskeletal dynamics through PAK1 activationand oxidant production. Journal of Virology. 2004;78(2):779–789.
Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B. Angiogenic properties of humanimmunodeficiency virus type 1 Tat protein. Proceedings of the National Academy of
Sciences of the United States of America. 1995;92(11):4838–484
Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M,
Camussi G, Rockl W, Bussolino F. The angiogenesis induced by HIV-1 tat protein ismediated by the Flk-1/KDR receptor on vascular endothelial cells. Nature Medicine.
;2(12):1371–1375.
Mitola S, Soldi R, Zanon I, Barra L, Gutierrez MI, Berkhout B, Giacca M, Bussolino F. Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells. Journal of Virology. 2000;74(1):344–353.
Scheidegger P, Weiglhofer W, Suarez S, Console S, Waltenberger J, Pepper MS, Jaussi R, Ballmer-Hofer K. Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. The Biochemical Journal. 2001;353(Pt3):569–578.
Chipitsyna G, Slonina D, Siddiqui K, Peruzzi F, Skorski T, Reiss K, Sawaya BE, Khalili K,Amini S. HIV-1 Tat increases cell survival in response to cisplatin by stimulating Rad51gene expression. Oncogene. 2004;23(15):2664–2671. DOI: 10.1038/sj.onc.1207417
Colombrino E, Rossi E, Ballon G, Terrin L, Indraccolo S, Chieco-Bianchi L, De Rossi A. Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Experimental Cell Research. 2004;295(2):539548. DOI: 10.1016/j.yexcr.2004.01.018
He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, Moore JP, Cerutti A. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. Journal of Immunology. 2006;176(7):3931–3941.
Walker DM et al. Transplacental carcinogenicity of 3’-Azido-3’Deoxythymidine in B6C3F1 mice and F344 rats. Environmental and Molecular Mutagenesis 48:283-298, 2007.
Maddaly Ravi, Solomon F.D Paul, M. Krishnan, K. Vijayalakshmi, V. VettriSelvi& Vikram R Jayanth (2004)Glycophorin-A Mutations as a Window to Study Carcinogenesis,International Journal of Human Genetics, 4:1, 51-54, DOI: 10.1080/09723757.2004.11885868.
Escobar PA et al. Genotoxicity assessed by the Comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC.Environmental and Molecular Mutagenesis 48: 330-343, 2007;48(3-4):330-343.
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
